ROPIVACAINE HYDROCHLORIDE
Clinical safety rating: safe
Animal studies have demonstrated safety
Ropivacaine is an amide-type local anesthetic that reversibly blocks nerve impulse propagation by inhibiting sodium ion influx via voltage-gated sodium channels in neuronal cell membranes.
| Metabolism | Primarily hepatic metabolism via CYP1A2 and CYP3A4 isoforms to 3-hydroxy-ropivacaine and other metabolites. |
| Excretion | Renal: 86% as metabolites and unchanged drug (primarily 3-hydroxy-ropivacaine and 4-hydroxy-ropivacaine glucuronides). Fecal: <1%. Biliary: minor. |
| Half-life | Terminal elimination half-life: 1.8–2.7 hours (mean 2.0 h) in adults. In neonates, prolonged to 3–6 hours due to immature hepatic clearance. |
| Protein binding | 94% bound to alpha-1-acid glycoprotein (AAG) and, to a lesser extent, albumin. Binding is concentration-dependent and saturable. |
| Volume of Distribution | Vd: 0.84 L/kg (adults). In neonates: 3–5 L/kg due to increased extracellular fluid volume and reduced protein binding. |
| Bioavailability | Epidural: 100% (systemic absorption). No oral formulation. Intravenous: 100%. Intrathecal: 100% (but rapid vascular uptake). |
| Onset of Action | Epidural: 10–20 minutes for sensory block. Peripheral nerve block: 15–30 minutes. Infiltration: 1–5 minutes. Intrathecal: 5–10 minutes. |
| Duration of Action | Epidural: 2–4 hours (sensory block). Peripheral nerve block: 4–8 hours (up to 12 h with epinephrine). Infiltration: 2–6 hours. Dose-dependent. |
| Molecular Weight | 328.9 |
0.2% to 0.5% solution; epidural: 15-30 mg bolus, then 6-14 mg/hour infusion; peripheral nerve block: 0.5% solution, 20-30 mL; local infiltration: 0.2% solution, up to 200 mg total.
| Dosage form | SOLUTION |
| Renal impairment | No specific dose adjustment required; caution in severe renal impairment (GFR < 30 mL/min) due to potential accumulation of metabolites. |
| Liver impairment | Child-Pugh Class A: No adjustment; Class B: Reduce dose by 50% and monitor closely; Class C: Contraindicated due to reduced clearance. |
| Pediatric use | Caudal block: 0.2% solution, 1 mL/kg (max 2 mg/kg); epidural: 0.1-0.2% solution, 0.5-1 mL/kg bolus then 0.1-0.4 mL/kg/hour infusion; maximum dose: 2 mg/kg. |
| Geriatric use | Elderly patients may require reduced doses due to decreased clearance; start at lower end of dosing range and titrate carefully; monitor for cardiovascular and neurological toxicity. |
| 1st trimester | Not recommended unless clearly necessary; crosses placenta rapidly; limited human data, animal studies show no teratogenicity. |
| 2nd trimester | Use only if benefit outweighs risk; placental transfer occurs; may cause fetal bradycardia. |
| 3rd trimester | Use with caution; may cause fetal bradycardia and neonatal respiratory depression; uterine blood flow reduction possible. |
Clinical note
Other local anesthetics or drugs that cause methemoglobinemia can have additive effects Can cause CNS toxicity and methemoglobinemia.
| Placental transfer | Rapidly crosses placenta; equilibration between maternal and fetal plasma occurs; protein binding limits transfer. |
| Breastfeeding | Excreted into breast milk in low amounts; unlikely to cause adverse effects in infant; use with caution, monitor for drowsiness or feeding difficulties. |
■ FDA Black Box Warning
None officially required by FDA, but risk of cardiac arrest and severe adverse effects with unintentional intravascular or high-dose administration exists.
| Common Effects | Hypotension |
| Serious Effects |
Hypersensitivity to ropivacaine or other amide-type local anestheticsSevere hypotensionComplete heart blockIntravenous regional anesthesia (Bier block)Infections at injection site
| Precautions | Risk of systemic toxicity (CNS and cardiac) with high doses or unintentional intravascular injection, Use with caution in patients with hepatic impairment, severe renal disease, or hypovolemia, May cause methemoglobinemia in rare cases, Monitor for signs of local anesthetic systemic toxicity (LAST) during administration |
| Food/Dietary | No clinically significant food interactions. No dietary restrictions required. |
Loading safety data…
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Ropivacaine crosses the placenta. No teratogenic effects have been observed in animal studies. In humans, use during the first trimester is generally not associated with major malformations based on limited data. During the second and third trimesters, local anesthetics can cause fetal bradycardia and acidosis, particularly with paracervical block. Risk of neonatal CNS depression if high doses are administered near term. |
| Fetal Monitoring | Continuous fetal heart rate monitoring during labor epidural administration. Maternal blood pressure monitoring for hypotension. Monitor for signs of systemic toxicity (CNS and cardiovascular) in both mother and fetus. For prolonged or high-dose infusions, monitor maternal and fetal acid-base status. |
| Fertility Effects | No specific studies on fertility effects in humans. Animal studies at doses equivalent to the maximum recommended human dose showed no impairment of fertility. Ropivacaine is not expected to significantly affect fertility. |
| Clinical Pearls | Use lower doses in elderly or debilitated patients due to reduced clearance. For epidural administration, test dose with epinephrine can detect intravascular injection. Avoid in patients with severe hepatic impairment due to prolonged half-life. Contraindicated for intravenous regional anesthesia (Bier block). Maximum dose: 3 mg/kg (single injection); 2 mg/kg for repeat doses. Onset of action: 10-20 minutes for epidural block. Duration: 2-6 hours depending on dose and site. |
| Patient Advice | Report any numbness or weakness that spreads beyond the intended area. · Seek immediate medical attention if you experience difficulty breathing, chest pain, or severe dizziness. · Avoid driving or operating heavy machinery until the effects of the medication have fully worn off. · Inform your doctor if you have liver disease, heart problems, or are taking blood thinners. · Do not suddenly stop taking this medication without consulting your doctor. |